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Determining who should get one of the extremely
scarce deceased donor liver grafts is becoming an
increasingly complex and diﬃcult problem. In the early
stages of the liver transplantation ﬁeld, centers became
aware of potential donors, decided whether to accept
this donation, and chose which candidate should receive
the graft without much consideration for the other cen-
ters and patients outside of their own area. However,
with the increasing success of liver transplantation, mat-
uration of the hepatitis C virus (HCV) epidemic, and
broadening of the indications for liver transplantation
to malignancies such as hepatocellular cancer and other
previously contraindicated diagnoses, the demand for
liver grafts has far outpaced the supply. This widening
gap has prompted governments and medical policy-0168-8278/$36.00  2009 Published by Elsevier B.V. on behalf of the Europ
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liver failure; KCC, King’s College Criteria.makers to develop strategies to address the question of
who should get the liver graft. In some cases, liver allo-
cation systems allow the transplant center to assign the
donated liver graft to a waiting candidate while, in other
systems, individual grafts are oﬀered to individual
patients.
With the understanding that the donor pool will
never be suﬃcient for the demand, liver transplant
practitioners have tried to expand the criteria that
deﬁne what grafts are acceptable for transplantation
while recognizing that these broader criteria also often
confer additional risks to recipients. Some of the most
diﬃcult decision-making has centered on determining
which patients with acute liver failure should receive
transplants since most will die without immediate
transplantation but also realizing that only a fraction
will recover. In the ﬁrst case, organ allocation systems
must deliver grafts in a very timely fashion to save a
life. In second instance, transplantation of a patient
who would have otherwise recovered condemns that
recipient to the life-long complications associated with
immunosuppressive medicine and deprives another
candidate of a graft that was not needed for the ﬁrst
candidate.
In this forum, the authors will address all of these
areas and focus on better deﬁning ‘‘Who should get
the liver graft?”, if not completely answering the ques-
tion outright. Ultimately, society at large, especially
the public who is supplying the organs for transplanta-
tion, will determine which candidates should or should
not get the graft.ean Association for the Study of the Liver.
Table 1
UKELD calculation.
UKELD = 5  {1.5  ln(INR) + 0.3  ln(Creat) + 0.6  ln(Br)  13  ln (Na) + 70}
where
INR = international normalized ratio
Creat = serum creatinine (lmol/l)
Br = serum bilirubin (lmol/l)
Na = serum sodium (mmol/l)
Table 2
Splitting criteria.
Donor livers should be split if not required for super urgent
transplantation or multivisceral grafting and the following criteria are
met:
1. Donor age <40
2. Weight >50 kg
3. ICU stay less than 5 days
The decision to split is based solely on these criteria and if a segmental
graft is required for a child in any paediatric center the splitting process
should be initiated independent of any decision on allocation of the
right liver to an adult patient.
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(Neville Jamieson)
In the United Kingdom the number of centers has
been centrally regulated and there remain only seven
liver transplant units for a population of 61 million. In
other countries the number of centers proliferated and
inequalities of access to transplantation became appar-
ent. Systems to address these issues were introduced
with variable levels of eﬀectiveness. In this section I will
highlight diﬀerences, comparing the UK center-based
system with a patient-based system such as that used
in the US.
2.1. Center-based systems
2.1.1. The current British model
Liver allocation in the UK was initially based on each
center being allocated a portion of the nation’s donor
pool reﬂecting its previous transplant activity and its
nationally contracted (and funded) activity with the
National Specialist Commissioning Advisory Group
(NSCAG). The donor area allocated to each center
being varied at regular intervals reﬂecting changes in
transplant activity and the number of donors in the hos-
pitals in the center’s donor region. This did not reﬂect a
center’s waiting list size, waiting list mortality or the
acuity of illness in the transplanted patients. Units were
however required to target recipients with an expected
post transplant survival of more than 50% at 5 years
[1]. Predictably, waiting times and waiting list mortality
varied widely.
Proposals for change raised issues about the value of
waiting time and waiting list deaths if the patients
listed by diﬀerent units had diﬀerent levels of illness
highlighting the need for more precise, patient-based
measures to be included in the allocation system.
Therefore agreed national minimal listing criteria [2]
were introduced with a minimum disease severity based
on the United Kingdom Model for End-stage Liver
Disease (UKELD) (Table 1). This has allowed move-
ment to a system of allocation of donor zone size based
on numbers of patients listed annually by each center
meeting these patient speciﬁc criteria. Overriding this
center-based allocation remains a national super urgent
scheme with speciﬁed criteria where the only further
allocation principle is time on the super urgent list.
Additionally for donors meeting speciﬁc criteria (Table
2) oﬀering the liver for splitting is obligatory, the left
lateral segment going to a child at one of three national
paediatric centers and the remaining right liver to the
retrieving center.
Thus UK organ allocation deﬁnes donor pools
based on patient-speciﬁc characteristics, but organ
allocation to individual patients remains at the cen-
ter’s discretion. Following listing UKELD is currentlyonly used internally by units in allocating available
organs to their own cases. A perceived advantage of
this system is that the recipients chosen for transplan-
tation can be tailored to the organ available. An
organ with identiﬁed donor risk factors and a high
donor risk index (see section by Robert J. Porte)
can be targeted appropriately to an intermediate risk
patient passing over a sicker patient in the anticipa-
tion that the center will be able to allocate a better
quality graft from their retrieval zone in the near
future. Similarly, it allows greater comfort in splitting
organs routinely to optimize graft availability for chil-
dren with center-based selection of appropriate smaller
adult recipients for the right liver graft.
Further reﬁnement of the system allowing a
national or regional ‘‘top band” listing placed just
below the super urgent category remains under discus-
sion to allow the sickest patients on the waiting list
priority between centers over a wider area reﬂecting
a donor population of approximately 20 million. This
banding represents a patient-speciﬁc approach based
on the UKELD score.
The British model is arguably not applicable to other
health systems without central control over the number,
location and activity of units. Even in the UK, the cen-
ter-based system may be reaching the end of the road
with the introduction of a national organ retrieval ser-
vice as part of an initiative to improve organ donation
which speciﬁcally separates the donation process from
organ allocation [3]. Implementation will initially be
based on retrieval zones and teams from the liver trans-
plant centers but may still require a new patient-based
organ allocation system to be developed based on
UKELD to determine where the retrieved organs will
be implanted.
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Dissatisfaction with inequality of access in the US on
the old waiting-time weighted system led to the revolu-
tion of the introduction of Model for End-stage Liver
Disease (MELD) into organ allocation [4,5]. Initially
aimed at the admirable challenge of reducing waiting list
death, it fortunately also did not impact patient survival
[6]. Interest in the system rapidly developed and MELD
is now widely applied as at least one parameter in allo-
cation in many countries. However this is not without its
own inequities. Additional points are required to allow
patients with tumors to be transplanted in a timely fash-
ion [6], particularly when the internal ﬂexibility inherent
in a center-based system is removed. Likewise, condi-
tions outside the standard run of intrinsic liver diseases
require ‘‘exception” status to allow patients with signif-
icant disease burden but with a low MELD to be trans-
planted. This requires complex, sometimes arbitrary,
calculations to allow appropriate additional weighting
and maintain equity of access.
A patient-based system obliges a center to consider
an organ for a single patient. If they pass over the
oﬀer for their patient they may lose the organ to
another center, this introduces an element of pressure
to accept a speciﬁc organ even though the surgeon
may have reservations about using this organ for a
speciﬁc patient. The next step in the development of
allocation algorithms is to match donor and recipient
risk index to optimize individual outcomes, patients
with the lowest disease burden also have to most to
lose from a poor quality graft [7]. These calculations
require accurate candidate and donor speciﬁc informa-
tion. Implementing such systems requires a patient-
based allocation system or a fully transparent center-
based system in which the center’s internal organ allo-
cation principles are precisely deﬁned.
There is a strong tide ﬂowing in the direction of
patient-based allocation even in the UK where the cen-
ter-based system has persisted to date. Much remains to
be done to reﬁne the existing allocation algorithms with
outstanding issues in deﬁning appropriate matching of
donor and recipient risk characteristics. The overall
aim remains optimal donor to recipient matching to
optimize organ usage, patient outcomes, and achieve a
fair distribution of access to transplantation over large
populations. Clearly, it is the patient who must always
be the central ﬁgure in the process if inequity is to be
avoided.3. Urgency versus utility versus survival beneﬁt?
(Douglas E. Schaubel)
The persistent shortage of donor livers only increases
the pressure on organ allocation policies to make thebest possible use of available organs. In this section we
compare and contrast the most frequently discussed
organ allocation schemes, in the context of deceased-
donor livers. Medical urgency, utility and (more
recently) transplant beneﬁt are three frequently dis-
cussed organ allocation schemes [8–16]. Under an allo-
cation system based on medical urgency (i.e., ‘‘sickest-
ﬁrst”), priority for transplantation is based on predicted
outcome in the absence of transplantation. With refer-
ence to liver transplantation and assuming that mortal-
ity is the outcome of interest, the wait list would be
sequenced in decreasing order of predicted pre-trans-
plant mortality. Conversely, under a utility-based sys-
tem, patients would be prioritized with respect to
predicted post-transplant survival. An allocation system
based on the concept of transplant survival beneﬁt
incorporates elements of both urgency- and utility-based
systems. Speciﬁcally, a survival beneﬁt-based system
would sequence wait-listed patients in decreasing order
of the predicted diﬀerence between post- versus pre-
transplant survival.
3.1. Urgency, utility and survival beneﬁt
There are advantages and disadvantages to each of
the urgency, utility, and survival beneﬁt allocation
schemes. The preference for a particular organ alloca-
tion scheme over its alternatives should be based on
the objectives of the allocation process. An allocation
system-based on medical urgency generally reduces the
number of wait list deaths by allocating donor livers
to patients subject to the highest wait list mortality.
Conversely, there would be fewer post-transplant deaths
if allocation was based on utility. Unlike either urgency-
or utility-based systems, survival beneﬁt-based alloca-
tion would reduce the total number of deaths (wait
list + post-transplant).
Allocation systems based on urgency and utility are
subject to one substantial limitation not shared by those
based on survival beneﬁt. Speciﬁcally, urgency-based
allocation is generally at the expense of utility and
vice-versa; stemming from the fact that wait list and
post-transplant mortality are positively correlated. By
selecting patients with the highest wait list death rate,
urgency-based allocation may select for transplantation
patients with the worst post-transplant outcomes. Con-
versely, by giving the highest priority to patients with
the highest post-transplant survival, utility-based alloca-
tion may result in the transplantation of patients unli-
kely to die on the wait list and, as a result, a higher
wait list mortality for the patient population as a whole.
Survival beneﬁt-based allocation does not seek to mini-
mize either wait list or post-transplant mortality, per se.
In fact, compared to a survival beneﬁt-based system, it
would be expected that an urgency-based system would
result in fewer wait list deaths, and that utility-based
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However, if the objective of the allocation system is to
minimize the total number of deaths to the patient pop-
ulation, then it would appear that a survival beneﬁt-
based system is indicated.
3.2. What are the pros and cons of the MELD system?
February 2002 marked the implementation of a
medical urgency allocation system based on the
MELD score [17–19]. It is useful to consider the pros
and cons the MELD system. First, although MELD is
a very strong predictor of wait list mortality, it is a
much weaker predictor of post-transplant mortality
[8]. This should not be viewed as a liability in and
of itself, though. If MELD were an equally strong
predictor of post-transplant mortality, the MELD
score would identify which patients would die with
or without a liver transplant, which of course would
be undesirable since allocation by MELD would then
merely shift mortality from pre- to post-transplant.
Second, several recent eﬀorts have been directed at
improving the MELD score, including re-weighting
the MELD components [20] and including serum
sodium [21,22]. Third, if liver allocation was driven
by survival beneﬁt there would be some reordering
of patients compared with ordering patients solely
by MELD alone. Merion et al. [8] reported that liver
transplant survival beneﬁt increases as MELD
increases, but this claim should be interpreted as
‘‘on average”. If MELD were the only predictor of
both wait list and post-transplant mortality, then allo-
cation by survival beneﬁt would indeed be equivalent
to allocation by MELD. However, there are several
factors in addition to MELD which predict wait list
and also post-transplant mortality [16]. In order to
maximize the lives saved through liver transplantation,
allocation should ideally be based on both utility and
urgency. In response, a transplant survival beneﬁt
allocation system is currently under consideration by
the OPTN Liver and Intestine Committee, with the
proposed beneﬁt score computed, using patient speciﬁc
variables.
Under a survival beneﬁt system, care should be
taken to ensure that various patient subgroups will
not be disadvantaged. The beneﬁt score distributions
in the OPTN database are quite similar across sub-
groups deﬁned by age, gender and race; which makes
sense for several reasons. Gender and race were delib-
erately excluded from the beneﬁt score calculation
and, age is only one of several patient characteristics.
Moreover, age is a weaker predictor of beneﬁt since it
aﬀects both wait list and post-transplant survival in
the same direction. Details of the proposed survival
beneﬁt score are available in Schaubel et al. [16].4. What to do with the expanded criteria graft?
(Robert J. Porte)
Most current organ allocation systems are based on
the assumption that all donor livers carry the same risk
of failure [23]. This, however, is not the case, and it has
been shown in numerous studies that the risk of graft
failure and recipient mortality diﬀers depending on the
quality of the donor liver [24–27]. Donor quality repre-
sents a continuum of risk rather than a dichotomous
diversion between ‘‘good” or ‘‘bad”. Increasing aware-
ness of the growing diversity in donor organ quality
has stimulated the debate on how this should be consid-
ered in organ allocation policies to avoid futility and
local diﬀerences in organ acceptance [23,27].
4.1. What is an expanded criteria donor graft?
An expanded criteria donor (ECD) implies a higher
risk in comparison with a reference donor. It has been
proposed not to use the term ‘‘marginal donors” in an
era of scarcity where every oﬀer for donation should
receive the highest respect [28,29]. In the past a refer-
ence, or ideal, donor was deﬁned as a donor with the fol-
lowing characteristics: age below 40 years, trauma as
cause of death, hemodynamically stable, no steatosis,
and no transmittable disease [28,29]. Although one
could categorize any donor not meeting these criteria
as ECD, this would be impractical because the use of
donors that do not meet all of these criteria has become
common practice [29,30]. Most reports have deﬁned an
ECD liver as an organ with an increased risk of poor
function or failure that may subject the recipient to
greater risks of morbidity or mortality [30,31]. In con-
trast to the low-risk grafts, which form a relatively
homogenous group, ECD grafts are quite heteroge-
neous. Although the impact of donor risk factors on
outcome has been analyzed in several studies, many of
these variables are not determined or known at the time
of organ procurement, such as duration of the cold and
warm ischemia times [26,28]. Therefore, it has been pro-
posed that these variables should not be included in the
deﬁnition of ECD livers [29].
There is a second category of ECD livers: grafts that
carry an increased risk of transmission of infection or
malignancy to the recipients. Although this group of
ECD livers may pose a (more long-term) risk to the reci-
pient, these livers may have characteristics that are other-
wise close to that of the reference donor [29,30]. This
category of ECD livers should therefore not be included
in studies on ECD livers that carry a risk of graft failure.
We here propose to separate these two types of ECD
donors and refer to them as type A (livers with an
increased risk of graft failure) and type B ECD livers (liv-
ers that carry an increased risk of disease transmission).
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as risk factors for early graft failure (ECD donors type
A) include age (>60 years), female donor (especially in
male recipients), steatosis, race, elevated liver function
tests, hypotension/ increased vasopressor use, non-
heart-beating donor (also known as donation after car-
diac death donors or DCD), split liver grafts, elevated
serum sodium levels, and prolonged cold ischemia time
(>12 h) [24,26,28,29]. Not all of these variables have
been unequivocally identiﬁed in all studies and the clin-
ical relevance of some remains debated (i.e. gender
match, race, elevated sodium levels). The three donor
variables that are most frequently encountered in daily
practice and that have been associated with a well-
established increased risk of early graft failure are
moderate to severe graft steatosis, advanced donor
age, and DCD.
4.2. Not all ECD livers carry the same risk
Although the qualitative eﬀects of individual donor
variables are well documented, the quantitative risk
associated with combinations of characteristics are
much less clear. In an attempt to develop a quantitative
donor risk index (DRI), Feng et al. identiﬁed seven
donor characteristics that independently predict a signif-
icantly increased risk of graft failure [28]. Donor age
over 40 years (and particularly over 60 years), DCD,
and split grafts were strongly associated with graft fail-
ure, while African-American race, less height, cerebro-
vascular accident and ‘other’ causes of brain death
were more modestly associated with graft failure. This
quantitative assessment of the risk of donor liver graft
failure using a DRI is an essential ﬁrst element in the
development of an allocation system that takes both
recipient and donor variables into consideration. How-
ever, several donor-related variables that are not
included in this DRI may be relevant as well, including
length of stay in the ICU and degree of steatosis [29,32].
4.3. Who should be oﬀered an ECD liver?
While few studies have focused on deﬁning the com-
binations of donor and recipient proﬁles, many centers
would traditionally not use an ECD liver for a high-risk
candidate [27,30]. Several studies have shown, for exam-
ple, that outcome after split liver transplantation is
worse when split grafts are used for very sick patients,
whereas good results can be obtained in stable recipients
[27,30]. However, recent studies have challenged the
conventional wisdom that high-risk donor livers should
not be used for high-risk patients [11,33]. In a study
based on a Markov simulation, Amin et al. [33] con-
cluded that patients with a high MELD score likely have
a lower probability of death overall if they accept a
higher-risk organ compared with waiting for a lower-risk organ. Using US data from the SRTR, Schaubel
et al. [11] calculated the survival beneﬁts of liver trans-
plantation as a function of candidate disease severity
as expressed by the MELD score and donor quality as
expressed by the DRI [28]. All recipients with MELD
P20 had a signiﬁcant survival beneﬁt from transplanta-
tion, regardless of DRI. These authors concluded that
pairing of high-DRI livers with low-MELD candidates
fails to maximize survival beneﬁt and may deny lifesav-
ing organs to high-MELD candidates who are at high
risk of death without transplantation. The main limita-
tion of this study, however, is that it is based on obser-
vational data of patients who have been transplanted
according to the conventional wisdom of preferably
not using high-risk donor organs in high-risk recipients.
These data may become less accurate when applied to
other populations which may receive a diﬀerent pattern
of care. Moreover, such models which are valid for pop-
ulations usually have wide conﬁdence intervals when
applied to individuals [2]. More importantly, the DRI
used in the study by Schaubel et al. does not include
data on the amount of graft steatosis. Although such liv-
ers may be used with acceptable outcome in the more
stable recipients with a low-MELD score [34,35], it
remains to be seen if the steatotic ECD graft will confer
a survival beneﬁt for the more ill candidate.
Apart from the severity of sickness, the etiology of
liver disease may play a role when matching donors
and recipients. For example, there is accumulating evi-
dence that grafts from donors with advanced age are
associated with more aggressive recurrence of HCV-
related liver disease and subsequently lower graft sur-
vival rates [23,29,35]. Therefore, it may be advisable
not to use some ECD livers for recipients with HCV.
However, a recent study by Majella Doyle et al. [36]
has shown that advanced donor age may have no signif-
icant impact on medium-term results after transplanta-
tion for HCV-related liver disease provided the cold
ischemia time is kept very short. Moreover, a strategy
of not using older donor livers for HCV-positive recipi-
ents would also result in a dilemma with the risk of
inequality among recipients, because other recipients
with diﬀerent etiologies of liver disease would also prefer
to have a young donor. This exempliﬁes the complexity
of developing an allocation system that considers in
detail both recipient and donor proﬁles.
On the other hand, speciﬁc ECD livers (here pro-
posed as type B ECD livers) could be well used for a spe-
ciﬁc group of recipients, whereas one should be very
reluctant to oﬀer such a liver to other potential recipi-
ents. For example, livers from hepatitis B core-positive
or HCV-positive donors can be used under certain con-
ditions to treat patients with end-stage liver disease due
to HBV or HCV, respectively.
Development of an ideal model to determine who
should get the ECD graft will be very diﬃcult given
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factors that may aﬀect outcome after transplantation.
Moreover, an allocation model based on matching valid
in one area may not be automatically applicable in
another area, given the signiﬁcant heterogeneity among
diﬀerent countries and regions regarding organ short-
age, waiting list mortality, legislation, and the presence
of alternatives to deceased donor liver transplantation
[29,30]. Therefore, in the absence of precise models for
speciﬁc situations, any (new) system for allocation will
need to include a mechanism for ensuring that the
responsible clinician has the ﬁnal decision in determin-
ing whether to use a given graft [2]. In addition, rigorous
attempts to keep the cold ischemia time as short as pos-
sible may provide signiﬁcant compensation for the two
most clinically relevant and prevalent donor risk factors:
age and steatosis [34,29,30]. Finally, novel strategies to
reduce graft injury during organ preservation, including
machine preservation and pharmacological interven-
tions, may prove to be critical to improve outcome after
transplantation of certain types of ECD livers.5. How do we assign priority to patients with
hepatocellular cancer (HCC)? (Richard Freeman)
In the US around 2000, policy-makers recognized the
need for more objective, patient-based measures to
deﬁne liver transplant need [37]. The most obvious,
objective condition that precludes a favorable LT out-
come is death on the waiting list. This was the rationale
for incorporating the MELD score. With reasonable
accuracy, the MELD score deﬁnes the risk of dying on
the waiting list for candidates with chronic liver disease
using only patient deﬁned variables not subject to obser-
ver biases [38]. However, there are other conditions that
do not necessarily carry an immediate risk of dying
without a transplant in the near term but do oﬀer a good
survival probability with liver transplantation, and for
which quality of life is superior to not performing the
transplant [39]. Among these is HCC.
5.1. What is an unfavorable stage of HCC for liver
transplantation?
For HCC candidates, in order to employ the organ
allocation concept of ‘‘risk of progression” to an unfa-
vorable stage while waiting requires that ‘‘unfavorable
stage” needs to be deﬁned. The Milan criteria (single
tumor <5 cm or no more than 3 tumors the largest
<3 cm) have been widely accepted and validated as a
good measure of a favorable stage and several studies
suggest that oﬀering LT to patients who progress
beyond Milan Criteria can result in inferior outcomes
[40]. Other less well validated criteria have been sug-
gested such as the UCSF [41] or Pittsburg [42] criteriaand these could be used as newer deﬁnitions of the
boundaries for deﬁning unfavorable stage. Although
not ﬁrmly established, many observers have argued that
an arbitrary deﬁnition of <50% 5-year patient survival
should set the limit of an unfavorable outcome, so what-
ever deﬁnition of unfavorable stage is used, most would
agree that this should deﬁne a post LT outcome that is
less than 50% patient survival 5 years after transplant.
Once unfavorable stage deﬁnitions have been estab-
lished, creating organ allocation policy using this pro-
gression to an unfavorable HCC stage concept
requires development of a statistical model to predict
progression beyond the unfavorable stage endpoint.
MELD was not designed to accurately predict HCC
progression beyond Milan Criteria or any other HCC
stage (e.g. UCSF criteria). In order to construct a pre-
dictive model for progression beyond the Milan Criteria
endpoint, patient-speciﬁc predictors of the risk of
removal (so-called drop out risk) need to be elucidated.
Since death also causes drop out for HCC patients,
MELD should be combined with tumor characteristics
to adequately estimate tumor progression and death rea-
sons for drop out as has been advocated by the Bologna
group [43].
5.2. What factors predict drop out for HCC candidates?
Using the US OPTN database, Freeman et al. con-
structed a Cox model to identify variables associated
with waiting list drop out for HCC candidates. We
found that, in addition to age, AFP, maximum tumor
size and MELD score were all predictive of drop out
on the waiting list [44]. In applying this model, MELD
was just as accurate in discerning those who would drop
out from the list as the combination of MELD, AFP
and maximum tumor size since most of the patients on
the waiting list have underlying viral disease as well.
The resulting MELD-HCC score can be applied to
derive a risk of wait list drop out analogous to the
MELD-deﬁned risk of waitlist drop out (death) for LT
candidates who do not have HCC. More recent updates
of these analyses have again conﬁrmed that the same
variables: MELD score, maximum tumor size, and
AFP, are associated with drop out from the waiting list
for HCC candidates. This is true even when a competing
risk analysis is used (Fig. 1). Note that all of these vari-
ables are relatively objective, patient-based parameters.
In all of these studies, tumor number was not associated
with drop out rate, a ﬁnding consistent with several
reports in the literature indicating that size of HCC
lesions, not number, is more often associated with vas-
cular invasion and a more aggressive phenotype.
In all of these analyses, administration of loco-regio-
nal treatments such as radiofrequency ablation, transar-
terial chemoembolization, percutaneous ethanol
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Fig. 1. Overall dropout rates for HCC and non-HCC candidates, listed
4/14/04-12/31/07 on the UNOS/OPTN liver transplant waiting list using
a competing risks statistical technique. All calculations are done from
time of listing for non HCC patients and from time of ﬁrst HCC
application acceptance for HCC patients. (courtesy of Dr. Erick
Edwards, used with permission.)
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to HCC candidates receiving enough priority on the
waiting list so that most are transplanted within 180
days of listing, a time period too short to see a signiﬁ-
cant eﬀect of AT arresting tumor progression. Nonethe-
less, there appears to be a positive selection eﬀect for AT
in that responders to AT prior to transplant appear to
have superior post LT survival [45,46] and in some sin-
gle center studies, responders to AT who are down-
staged from beyond Milan Criteria to within Milan
Criteria, have excellent post transplant survivals [47].
Based on these results, some have argued that response
to AT, down staging to within Milan Criteria, or at least
arresting of progression of HCC by the AT that allows
for more prolonged waiting on the list without progres-
sion, should be used as a positive selection factor in allo-
cation policy for HCC candidates.
5.3. Are there better ways of assigning the liver graft for
HCC candidates?
Using a HCC-MELD score scheme for liver prioriti-
zation oﬀers several advantages over the current US sys-
tem. It provides a continuous rather than categorical
grading of need. In contrast to the current system a
HCC-MELD score, by maintaining the MELD score
within HCC allocation ensures that some priority based
on the underlying liver disease severity is included. The
contribution of the underlying liver disease to drop
out on the waiting list for HCC candidates has been
appreciated by other groups [43].
In summary, we now have a wealth of data suggesting
that LT oﬀers the best oncologic option for patients with
HCC. Prioritizing who gets this treatment however,
depends, not only on balancing individual justice and
utility for the HCC candidates, it requires taking into
account the other candidates who do not have malig-nancy and their likely success rates. Making progress
in achieving a reasonable balance requires that objec-
tive, patient-based measures and endpoints are used
for candidates with HCC and those without HCC alike.6. Which Patients with fulminant hepatitis should get a
liver graft and how do we assign Priority?
(Federico G. Villamil)
Acute liver failure (ALF) results in 70–80% mortality
unless liver transplantation (OLT) is performed [48].
Based on the low rates of spontaneous recovery a simple
answer to the question of which patients with ALF
should get a liver graft is ‘‘the majority”. However,
due to current organ scarcity and the consequences of
life-long immunosuppression, maximal eﬀorts are
required to avoid unnecessary OLT. The keys for suc-
cess in managing patients with ALF are early assessment
of prognosis and availability of an organ donor in a
timely fashion. Ideal prognostic markers should be able
to distinguish, shortly after referral, patients who will
survive with medical therapy, and thus with no need
for OLT, from those with poor outcome who should
be transplanted early and before the onset of irreversible
complications or multi-organ failure. In addition, eﬀec-
tive prognostic markers should be simple-to-use and
universally applicable to all patients with ALF irrespec-
tive of etiology or geography.
Many clinical, laboratory, radiological and histologi-
cal markers and composite scores have been proposed to
assess prognosis in ALF but at present none of them can
predict outcome with absolute certainty [49]. Of all
prognostic scores, the King’s College Criteria (KCC),
with separate models for acetaminophen and other
causes of ALF, are today the most widely accepted
and are used as the standard to which new scores are
compared [50]. Reported experience has shown that
KCC are accurate for predicting death (positive predic-
tive values of 80–100%) but are less eﬀective to identify
patients who will recover spontaneously (negative pre-
dictive values of 23–70%) [51]. Despite this limitation,
the score is clinically useful because it identiﬁes patients
requiring OLT irrespective of the severity of
encephalopathy.
6.1. Comparing models for predicting mortality risk from
ALF
Kremers et al. demonstrated that among 312 patients
with non-acetaminophen ALF listed in the US as Status
1, the Model for End-stage Liver Disease (MELD) was a
statistically signiﬁcant predictor of mortality and overall
survival [52]. Yantorno et al. recently showed that
MELD was signiﬁcantly more accurate (concordance
statistics) than KCC and Clichy’s Criteria [53] to predict
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acetaminophen. Concordance scores were 0.95, 0.74
(p = 0.003) and 0.68 (p = 0.001), respectively. More
recently we conﬁrmed that the superiority of MELD
was independent of etiology and clinical variants of
the disease [54].
Even though our results have not been fully con-
ﬁrmed in other series that evaluated diﬀerent cut-oﬀ val-
ues for MELD [55–58], the challenging question is
whether prognosis of ALF should be assessed with con-
tinuous or categorical scores including laboratory values
that remain ﬁxed above the deﬁned threshold and thus
limit its discriminatory ability. When using KCC,
patients with serum bilirubin values of 18 or 40 mg/dL
and INR values of 3.6 or 6.0 are assigned to the same
prognostic category. In contrast, MELD score progres-
sively increases with worsening of its components and
may better identify individual patients with higher risk
of death. Whether to use categorical or continuous
scores in ALF is an important issue and resembles the
controversy of whether MELD or the Child-Pugh score
are preferable to assess outcome of patients with cirrho-
sis. Overall, no prognostic score will completely replace
good clinical judgment because at present there is no
perfect formula to indicate OLT but one would expect
models that more closely resemble the continuous nat-
ure of clinical disease are likely to be more useful. The
course of ALF is largely unpredictable and therefore
in clinical practice severity of encephalopathy, coagu-
lopathy and extrahepatic complications are evaluated
on a day-to-day and even hour-to-hour basis and many
times the ﬁnal decision to proceed or not with OLT is
made when an organ becomes available.
OLT is a true life-saving procedure for patients
with ALF. However, the rapidity of disease progres-
sion allows a narrow window for performance of
OLT in a timely fashion. Patients with ALF are given
the top priority for graft allocation worldwide. Still, a
substantial number of patients die on the waiting list,
especially in areas where deceased donors are not
readily available. OLT should not be indicated too
early in patients with favorable prognosis but deﬁ-
nitely not too late at a point where the procedure
may be futile loosing both the patient and the donor
organ. ALF is an heterogeneous condition. Patients
with hyperacute forms rapidly progress to grade 4
coma due to cerebral edema [59]. In contrast, subacute
forms are characterized by slowly progressive coagu-
lopathy and encephalopathy and in most cases death
occurs in weeks rather than in days. Despite having
poor outcome without OLT, the time-period to ﬁnd
a suitable organ in subacute forms is much longer
than in the hyperacute variants. Therefore, it is likely
that among candidates with ALF listed in the emer-
gency category there are subgroups with more severe
disease and more urgent need for OLT.6.2. Should ‘‘sickest ﬁrst” apply to liver allocation for
acute liver failure?
A relevant question to be addressed is whether ‘‘the
sickest ﬁrst” principle should also be applied to ALF.
Kremers et al. showed that among 720 candidates listed
as Status 1 in the US, MELD scores were signiﬁcantly
higher in patients with ALF than in those requiring
emergency re-OLT for primary non-function or hepatic
artery thrombosis [52]. In addition, this study showed
that patients with non-acetaminophen ALF had the
highest waitlist mortality, the best outcome when OLT
was performed expeditiously and therefore the greatest
transplant beneﬁt. These ﬁndings suggest that criteria
for allocation of donor organs to patients in the emer-
gency category should be redeﬁned. Instrumentation of
such a new policy will require stratiﬁcation of listed
patients by MELD or other continuous disease severity
scale using patient-based variables. Improved fairness of
the allocation system may increase the applicability of
OLT in ALF and reduce the need for live donors.7. Summary and conclusions (Richard Freeman)
Assigning priority to receive any scarce resource has
remained the subject of intense ethical debates for centu-
ries. In the US, Federal law mandates that a sickest ﬁrst
system should be employed for ranking candidates for
liver transplantation (LT) based on ‘‘medical need” [60].
Need for LT be conceptualized by deﬁning a risk to
progressing to a condition that precludes a favorable
outcome with LT. In the past this need was mostly
deﬁned by clinicians observing patients and, since these
observations were clinician-based, they were subject to
all the biases and subjective judgments each clinician
brought with him or her to the priority decision-making
process. These subjective priority measures were also
inconsistently interpreted, sometimes in favor of trans-
plant centers, or institutional allegiances, more than
individual patient’s best interests.
The preceding discussion makes a few points clear.
Increasingly, no matter whether allocation policy oﬀers
the graft directly to the patient or to the center, deter-
mining ‘‘who should get the liver graft” is being done
with more sophisticated prognostic modeling based on
patient-speciﬁc, rather than observer-deﬁned measures.
As discussed by Jamieson, even in a primarily center-
based system, the most urgent candidates are prioritized
by patient speciﬁc variables and UKELD is used within
centers to decide ‘‘who should get the liver graft.” In
patient-based allocation systems, physicians still decide
whether the graft oﬀered to the individual patients
should be used in that circumstance, but organ oﬀers
and the measurement of physician behavior is more
readily deﬁned by objective, patient-based variables. In
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cit survival beneﬁt calculations as outlined by Schaubel
that are not possible without well deﬁned measures.
Included in the ‘‘who should get the liver graft” deliber-
ations, are assessments of graft viability and function
probabilities, particularly for the less than optimal grafts
as described earlier by Robert J. Porte. These donor
assessments are also increasingly being measured by spe-
ciﬁc donor criteria although standardizing and including
all of the relevant variables has not been fully realized to
date. The increasing prevalence of HCC worldwide
introduces the need to deﬁne more precisely, not only
the immediate short-term risks of cancer progression,
but also the long-term risks of tumor recurrence as well
as patient survival. Perhaps the most critical decision-
making for the acute liver failure patients is not ‘‘who
should the graft”, but who should not get the graft. As
outlined by Villamil, the clinician is faced with models
that are very good at predicting which patient will likely
die of acute liver failure but our models are less helpful
in determining which patients will not die without the
graft.
We have tried to provide the additional data and insight
for liver transplant professionals facing the question of
‘‘who should get the liver graft” based on the evidence
and point out where the evidence is weak. Hopefully this
will stimulate further research in these areas.Acknowledgement
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